Switching from traditional cigarettes to heated tobacco products (HTPs) like IQOS is often considered a harm reduction strategy. While industry data suggests HTPs may expose users to fewer respiratory toxins, their effect on respiratory infections remains unclear.
This explainer reviews current understanding and highlights the need for further research to determine if HTPs can lessen the severity or risk of pulmonary infections compared to conventional smoking.